Screening of clones for periplasmic secretion, soluble and inclusion body expression in E.coli
Screening of clones for expression of secreted protein in yeast (Pichia pastoris, Saccharomyces, Hansenula)
Cell banking services from development (RCB) to GMP (MCB/WCB)
Stability studies
Documented cell line generation for easy transfer to GMP

For mammalian cell line development, we can tap into the expertise of the Eurofins network or carefully selected partners.

Our mammalian cell culture facilities offer:

Flexible cell culture systems: our platform supports fed-batch and perfusion processes. From small-scale parallel testing (100-250 mL) and bench scale (5-10L) capabilities to pilot manufacturing (50-200L) and by April 2026, large scale (2000L) with 500L perfusion capabilities, our upstream team can deliver scalable process.

Customised DSP solutions: alongside broad DSP capabilities, we prioritise viral safety in mammalian projects through built-in viral clearance steps and coordinated studies.

Analytical development and bioassay capabilities: for advanced evaluation and characterisation of critical quality attributes

GMP compliance: our facilities and operations are GMP compliant

We specialise in the development and production of recombinant proteins, enzymes and other microbial-based products. Key features of our microbial production services include:

High-efficiency fermentation: from process development in parallel bioreactor systems to stainless steel and single-use fermenters at various scales, we can support small-scale productions as well as large-scale manufacturing using batch or fed-batch processes.

Targeted expression: next to cytosolic protein production, we can engineer bacterial systems to direct protein expression to the periplasmic space, facilitating protein folding and purification.

Scalable manufacturing: based on an understanding of critical process parameters, we develop processes with commercial manufacturing as a goal.

Comprehensive downstream processing: our DSP capabilities include centrifugation, high pressure cell disruption, refolding of inclusion bodies, precipitation, chromatography and filtration (TFF, UF/DF and end filtration)

Regulatory compliance

Phage lysins, also known as endolysins, are enzymes produced by bacteriophages to facilitate the release of newly formed phage particles from bacterial hosts. In medicine, phage lysins are being explored for their potential therapeutic applications. This class of proteins was shown in various animal models to be a promising alternative or complement to traditional antibiotics and to combat the increasing threat of antibiotic-resistant bacteria. 

It is important to rely on a CDMO with a solid experience in this field, as producing endolysins recombinantly presents different challenges, including:

Toxicity of the target protein to the host cell
Formation of inclusion bodies and aggregates
Protein folding and stability to maintain enzymatic activity
Purification challenges

We have successfully supported several endolysin projects from early development to clinical manufacturing.